Opinion
Video
Author(s):
Stacey Cohen, MD, discusses the rationale and study design of the phase 2/3 CIRCULATE-NORTH AMERICA study evaluating adjuvant chemotherapy selection based on MRD, and the panel discusses barriers to enrollment.
ctDNA Generates Momentum in Adjuvant Stage II/III Colon Cancer Setting
Delve into Recent NCCN Guideline Updates for Hepatobiliary and CRC Management: With Alan P. Venook, MD
Telisotuzumab Adizutecan Represents a Novel c-Met–Targeting ADC in MET-Amplified CRC
Park and Kasi Expand on Perioperative Immunotherapy Updates in CRC
Treatment Personalization Is Poised to Define New Era of mCRC Therapy
Sotigalimab May Be a Safe and Feasible Addition to the Rectal Cancer Chemoradiotherapy Paradigm
RVU120 Shows Early Promise in R/R Metastatic or Advanced Solid Tumors
The WEE1 Inhibitor APR-1051 Shows Early Safety and Tolerability in Advanced, Mutated Solid Tumors
TYRA-300 Is Safe, Generates Preliminary Antitumor Activity in FGFR3+ Metastatic Urothelial Cancer
Experts Highlight Noteworthy Research From the 2024 ESMO Congress